Mechanism of action of beta-blocking agents in heart failure (Q41669348)

6 October 2017

1 reference

title

Mechanism of action of beta-blocking agents in heart failure (English)

1 reference

6 October 2017

0 references

M R Bristow

1

1 reference

PubMed ID

9412540

6 October 2017

language of work or name

English

0 references

publication date

1 December 1997

1 reference

American Journal of Cardiology

6 October 2017

1 reference

6 October 2017

80

1 reference

6 October 2017

11A

1 reference

6 October 2017

26L-40L

1 reference

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group

6 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Beta-adrenergic function in heart muscle disease and heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Rationale for beta-adrenergic blocking drugs in cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

The adrenergic nervous system in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Subsensitivity of the failing human heart to isoprenaline and milrinone is related to beta-adrenoceptor downregulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Reduced beta 1 receptor messenger RNA abundance in the failing human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Differences in cardioprotective efficacy of adrenergic receptor antagonists and Ca2+ channel antagonists in an animal model of dilated cardiomyopathy. Effects on gross morphology, global cardiac function, and twitch force

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Effects of chronic beta-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Adrenergic effects on the biology of the adult mammalian cardiocyte

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Isolated ventricular myocytes from failing and non-failing human heart; the relation of age and clinical status of patients to isoproterenol response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Adrenergic nervous system in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Adverse consequences of high sympathetic nervous activity in the failing human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Myocardial Performance and Extracellular Ionized Calcium in a Severely Failing Human Heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Role of beta-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Mechanism of noradrenaline-induced heterologous desensitization of adenylate cyclase stimulation in rat heart muscle cells: increase in the level of inhibitory G-protein alpha-subunits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Selective beta 1-adrenoceptor blockade enhances positive inotropic responses to endogenous catecholamines mediated through beta 2-adrenoceptors in human atrial myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Cardiac beta-adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury. Evidence for catecholamine-mediated myocardial damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Why do patients with congestive heart failure tolerate the initiation of beta-blocker therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Differences in cardiac calcium release channel (ryanodine receptor) expression in myocardium from patients with end-stage heart failure caused by ischemic versus dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Cellular mechanisms in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Anti-adrenergic effects of angiotensin converting enzyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Functional beta3-adrenoceptor in the human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Molecular characterization of the human beta 3-adrenergic receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Alpha-adrenoceptors and alpha-adrenoceptor-mediated positive inotropic effects in failing human myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Effects of myocardial alpha 1-adrenergic receptor stimulation and blockade on contractility in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Inotropic effects of angiotensin II on human cardiac muscle in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium. An in vitro study under physiological experimental conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Activation of the STAT pathway by angiotensin II in T3CHO/AT1A cells. Cross-talk between angiotensin II and interleukin-6 nuclear signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Evidence from use of neuronal uptake inhibition that β1-adrenoceptors, but not β2-adrenoceptors, are innervated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Regulation of the mRNA-binding protein AUF1 by activation of the beta-adrenergic receptor signal transduction pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Changes in myocardial and vascular receptors in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Phosphorylation and desensitization of the human beta 1-adrenergic receptor. Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Comparative rates of desensitization of beta-adrenergic receptors by the beta-adrenergic receptor kinase and the cyclic AMP-dependent protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Immunodetectable levels of the inhibitory guanine nucleotide-binding regulatory proteins in failing human heart: discordance with measurements of adenylate cyclase activity and levels of pertussis toxin substrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Increase in myocardial Gi-proteins in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Radioimmunochemical quantification of Gi alpha in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Decreased Gs alpha mRNA levels accompany the fall in Gs and adenylyl cyclase activities in compensated left ventricular hypertrophy. In heart failure, only the impairment in adenylyl cyclase activation progresses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Differentiation of hemodynamic, humoral and metabolic responses to beta 1- and beta 2-adrenergic stimulation in man using atenolol and propranolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Impaired chronotropic response to exercise in patients with congestive heart failure. Role of postsynaptic beta-adrenergic desensitization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Molecular and cellular mechanisms of myocardial failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Reduced Contraction and Altered Frequency Response of Isolated Ventricular Myocytes From Patients With Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

The failing human heart is unable to use the Frank-Starling mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Existence of the Frank-Starling mechanism in the failing human heart. Investigations on the organ, tissue, and sarcomere levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

The molecular biology of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Creatine kinase system in failing and nonfailing human myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Cytoskeletal role in the contractile dysfunction of hypertrophied myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Dilated cardiomyopathy associated with deficiency of the cytoskeletal protein metavinculin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

REDUCTION OF STRESS/ CATECHOLAMINE-INDUCED CARDIAC NECROSIS BY BETA1-SELECTIVE BLOCKADE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Cardiovascular injury induced by sympathetic catecholamines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

beta Adrenergic receptor desensitisation may serve a cardioprotective role

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Apoptosis in pressure overload-induced heart hypertrophy in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Apoptosis in myocytes in end-stage heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Late effects of acute infarct dilation on heart size: a two dimensional echocardiographic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Ventricular remodelling: consequences and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Wall stress and patterns of hypertrophy in the human left ventricle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Usefulness of bucindolol in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Effects of beta-adrenergic blockade on survival of patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Cardiac adrenergic receptor effects of carvedilol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Second- and third-generation beta-blocking drugs in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Effect of propranolol after acute myocardial infarction in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900846-1

10.1016/S0002-9149(97)00846-1

7 January 2021

Identifiers

DOI

1 reference

6 October 2017

1 reference

PubMed ID

9412540